Keyphrases
Neoadjuvant
100%
Hormone Therapy
100%
Locally Advanced Prostate Cancer
100%
Neoadjuvant Endocrine Therapy
100%
Radiotherapy
83%
Prostatectomy
83%
Overall Survival
83%
Primary Therapy
50%
Disease-free Survival
50%
Survival Benefit
50%
Disease-specific Survival
50%
Meta-analysis
33%
Adjuvant Therapy
33%
Clinical Benefit
33%
Local Control
33%
Patient Well-being
33%
Positive Surgical Margin
33%
Hormonal Deprivation
33%
Pathological Variables
33%
Prostate Cancer
16%
Randomized Trial
16%
Politicians
16%
Local Level
16%
Androgen Deprivation Therapy
16%
Subgroup Analysis
16%
Clinical Disease
16%
Cost Implications
16%
Recurrent Disease
16%
Outcome-based
16%
MEDLINE
16%
Intention-to-treat Principle
16%
Comparable Data
16%
Embase
16%
Clinical Variables
16%
Recurrence Rate
16%
Radical Prostatectomy
16%
Significant Disease
16%
Cochrane Library
16%
Pathological Stage
16%
Selection Criteria
16%
Search Strategy
16%
Lymph Node Involvement
16%
Gynecomastia
16%
Early Prostate Cancer
16%
T1-T2
16%
Science Citation Index
16%
Gleason Score
16%
Quasi-randomized Controlled Trial
16%
Biochemical Recurrence-free Survival
16%
Clinical Costs
16%
Radical Radiotherapy
16%
Gleason
16%
Hot Flushes
16%
Clinical Toxicity
16%
PSA Level
16%
Library Science
16%
T3, T4
16%
Margin Rate
16%
Local Advanced
16%
Deprivation Therapy
16%
Clinical Outcomes
16%
Organ-confined
16%
Medicine and Dentistry
Prostate Cancer
100%
Hormone Therapy
100%
Adjuvant
100%
Prostatectomy
60%
Radiation Therapy
60%
Overall Survival
50%
Disease Free Survival
40%
Disease Specific Survival
30%
Health Care Cost
20%
Quality of Life
20%
Systematic Review
20%
Meta-Analysis
20%
Surgical Margin
20%
Adjuvant Therapy
20%
High Risk Population
10%
Clinician
10%
Subgroup Analysis
10%
Randomized Controlled Trial
10%
Hot Flush
10%
Recurrent Disease
10%
Lymph Node
10%
Recurrence Risk
10%
Side Effect
10%
Intention-to-Treat Analysis
10%
Gleason Score
10%
Gynecomastia
10%
Pathological Staging
10%
Androgen
10%
Nursing and Health Professions
Hormonal Therapy
100%
Prostate Cancer
100%
Adjuvant
100%
Radiotherapy
60%
Prostatectomy
60%
Overall Survival
50%
Disease Free Survival
40%
Disease Specific Survival
30%
Systematic Review
20%
Quality of Life
20%
Meta Analysis
20%
Adjuvant Therapy
20%
Clinical Outcome
10%
Intention to Treat Analysis
10%
Cochrane Library
10%
SciSearch
10%
Recurrent Disease
10%
Recurrence Risk
10%
Side Effect
10%
High Risk Population
10%
Hot Flush
10%
Gleason Score
10%
Androgen
10%
Gynecomastia
10%
Pharmacology, Toxicology and Pharmaceutical Science
Endocrine Therapy
100%
Prostate Cancer
100%
Adjuvant
100%
Overall Survival
55%
Disease Free Survival
44%
Disease Specific Survival
33%
Randomized Controlled Trial
11%
Hormone Cancer Therapy
11%
Side Effect
11%
Recurrent Disease
11%
Recurrence Risk
11%
Gleason Score
11%
Hot Flush
11%
Androgen
11%
Gynecomastia
11%
Neuroscience
Hormone Therapy
100%
Radiation Therapy
60%
Meta-Analysis
20%
Adjuvant Therapy
20%
Randomized Controlled Trial
10%
Androgen
10%
Prostate
10%
Lymph Node
10%